• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta biomaterialia >3D bioprinting for drug discovery and development in pharmaceutics
【24h】

3D bioprinting for drug discovery and development in pharmaceutics

机译：3D Bioplint用于药物的药物发现和发展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Successful launch of a commercial drug requires significant investment of time and financial resources wherein late-stage failures become a reason for catastrophic failures in drug discovery. This calls for infusing constant innovations in technologies, which can give reliable prediction of efficacy, and more importantly, toxicology of the compound early in the drug discovery process before clinical trials. Though computational advances have resulted in more rationale in silico designing, in vitro experimental studies still require gaining industry confidence and improving in vitro-in vivo correlations. In this quest, due to their ability to mimic the spatial and chemical attributes of native tissues, three-dimensional (3D) tissue models have now proven to provide better results for drug screening compared to traditional two-dimensional (2D) models. However, in vitro fabrication of living tissues has remained a bottleneck in realizing the full potential of 3D models. Recent advances in bioprinting provide a valuable tool to fabricate biomimetic constructs, which can be applied in different stages of drug discovery research. This paper presents the first comprehensive review of bioprinting techniques applied for fabrication of 3D tissue models for pharmaceutical studies. A comparative evaluation of different bioprinting modalities is performed to assess the performance and ability of fabricating 3D tissue models for pharmaceutical use as the critical selection of bioprinting modalities indeed plays a crucial role in efficacy and toxicology testing of drugs and accelerates the drug development cycle. In addition, limitations with current tissue models are discussed thoroughly and future prospects of the role of bioprinting in pharmaceutics are provided to the reader.
机译：成功推出商业药物需要大量的时间和财政资源投入，其中晚期失败成为药物发现中灾难性失败的原因。这需要戒断技术不断创新，这可以可靠地预测疗效，更重要的是，在临床试验之前，在药物发现过程中早期的复合毒理学。虽然计算进步导致硅设计中的更理由，但体外实验研究仍然需要行业的信心和改善体外相关性的相关性。在这种任务中，由于它们模仿本地组织的空间和化学属性，与传统的二维（2D）模型相比，现在已经证明，已经证明了三维（3D）组织模型为药物筛选提供了更好的结果。然而，在实现3D模型的全部潜力方面，在体外制造活组织的制造仍然是瓶颈。 BioPlinting最近的进展提供了一种有价值的工具来制造仿生构造，可用于药物发现研究的不同阶段。本文介绍了对制药制备药物研究的生物监测技术的第一综述。对不同生物监测方式的比较评估进行了评估制造3D组织模型的性能和能力，因为对生物制品的危重选择的危重选择性，确实在药物的疗效和毒理学测试中起着至关重要的作用，并加速了药物开发循环。此外，彻底地讨论了利用当前组织模型的限制，并将对读者提供了生物印刷品在药物中的作用的未来前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号